trending Market Intelligence /marketintelligence/en/news-insights/trending/1BEy6tinzpozqueU__5trA2 content esgSubNav
In This List

US FDA approves Roche's lung cancer companion diagnostic

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


US FDA approves Roche's lung cancer companion diagnostic

The U.S. Food and Drug Administration approved Roche Holding Ltd.'s VENTANA ALK (D5F3) CDx Assay as a companion diagnostic to identify anaplastic lymphoma kinase-positive non-small cell lung cancer patients eligible for treatment with Novartis AG's Zykadia drug.

The in vitro diagnostic assay will be used to detect the anaplastic lymphoma kinase protein in non-small cell lung carcinoma tissue on BenchMark XT or BenchMark ULTRA automated staining instrument. It is the only immunohistochemistry test approved by the FDA as a companion diagnostic for Zykadia.